Volume 2 - Issue 1, January - February 2026

Ovarian cancer is a deadly gynecologic cancer, often diagnosed late due to vague symptoms, leading to poor survival, but improved treatments like surgery, platinum chemo, and targeted drugs (PARP inhibitors, bevacizumab) are increasing survival, especially with genetic awareness (BRCA mutations). Most cases (90%) are epithelial, primarily high-grade serous, with key risk factors being age, genetics (BRCA1/2), family history, and nulliparity, while oral contraceptives and childbirth reduce risk. Treatment involves cytoreductive surgery and chemotherapy, with maintenance targeted therapies and new approaches for recurrence.

Dr.D.Rama Brahma Reddy, CH.Naga Sowjanya, SK.Hajmoon,"Review on Ovarian Cancer" International Journal of Scientific Research and Engineering Development, V2(1): Page(532-540) Jan-Feb 2026. ISSN: 3107-6513. www.ijamred.com. Published by Scientific and Academic Research Publishing.